CLOs on the Move

Q2 Solutions

www.q2labsolutions.com

 
Q² Solutions, a Quintiles Quest joint venture Launched in 2015, Q² Solutions (pronounced Q-squared) is a leading global clinical trials laboratory services organization. We help biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q² Solutions is a quality driven, responsive partner with strong global experience and deep scientific and medical expertise. The Q² Solutions joint venture was formed by Quintiles and Quest Diagnostics, combining the best of each parent organizations clinical trials laboratory services capabilities.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Hillsdale Community Health Center

Hillsdale Community Health Center is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Hillsdale, MI. To find more information about Hillsdale Community Health Center, please visit www.hchc.com

Spring Fertility

At Spring, we`re dedicated to helping people bring healthy children into the world. We`re also committed to providing the most personalized, patient-centered and compassionate care, with individualized treatment plans designed for your unique needs.

American Health Medicare

American Health Medicare is a San Juan, PR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Janet, Jenner, and Suggs

Janet, Jenner, & Suggs LLC is a Pikesville, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Diagnocure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.